Literature DB >> 25642707

Evasion of inflammasome activation by microbial pathogens.

Tyler K Ulland, Polly J Ferguson, Fayyaz S Sutterwala.   

Abstract

Activation of the inflammasome occurs in response to infection with a wide array of pathogenic microbes. The inflammasome serves as a platform to activate caspase-1, which results in the subsequent processing and secretion of the proinflammatory cytokines IL-1β and IL-18 and the initiation of an inflammatory cell death pathway termed pyroptosis. Effective inflammasome activation is essential in controlling pathogen replication as well as initiating adaptive immune responses against the offending pathogens. However, a number of pathogens have developed strategies to evade inflammasome activation. In this Review, we discuss these pathogen evasion strategies as well as the potential infectious complications of therapeutic blockade of IL-1 pathways.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25642707      PMCID: PMC4319426          DOI: 10.1172/JCI75254

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  113 in total

1.  Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. The Interleukin-1 Receptor Antagonist Sepsis Investigator Group.

Authors:  S M Opal; C J Fisher; J F Dhainaut; J L Vincent; R Brase; S F Lowry; J C Sadoff; G J Slotman; H Levy; R A Balk; M P Shelly; J P Pribble; J F LaBrecque; J Lookabaugh; H Donovan; H Dubin; R Baughman; J Norman; E DeMaria; K Matzel; E Abraham; M Seneff
Journal:  Crit Care Med       Date:  1997-07       Impact factor: 7.598

2.  Dose-range and dose-frequency study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis. The IL-1Ra Arthritis Study Group.

Authors:  G V Campion; M E Lebsack; J Lookabaugh; G Gordon; M Catalano
Journal:  Arthritis Rheum       Date:  1996-07

3.  A multicentre, double blind, randomised, placebo controlled trial of anakinra (Kineret), a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis treated with background methotrexate.

Authors:  S B Cohen; L W Moreland; J J Cush; M W Greenwald; S Block; W J Shergy; P S Hanrahan; M M Kraishi; A Patel; G Sun; M B Bear
Journal:  Ann Rheum Dis       Date:  2004-04-13       Impact factor: 19.103

4.  Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. Phase III rhIL-1ra Sepsis Syndrome Study Group.

Authors:  C J Fisher; J F Dhainaut; S M Opal; J P Pribble; R A Balk; G J Slotman; T J Iberti; E C Rackow; M J Shapiro; R L Greenman
Journal:  JAMA       Date:  1994-06-15       Impact factor: 56.272

5.  Viral inhibition of inflammation: cowpox virus encodes an inhibitor of the interleukin-1 beta converting enzyme.

Authors:  C A Ray; R A Black; S R Kronheim; T A Greenstreet; P R Sleath; G S Salvesen; D J Pickup
Journal:  Cell       Date:  1992-05-15       Impact factor: 41.582

6.  Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate.

Authors:  Mark C Genovese; Stanley Cohen; Larry Moreland; Deborah Lium; Sean Robbins; Richard Newmark; Pirow Bekker
Journal:  Arthritis Rheum       Date:  2004-05

7.  Effective use of the recombinant interleukin 1 receptor antagonist anakinra in therapy resistant systemic onset juvenile rheumatoid arthritis.

Authors:  James W Verbsky; Andrew J White
Journal:  J Rheumatol       Date:  2004-10       Impact factor: 4.666

8.  Initial evaluation of human recombinant interleukin-1 receptor antagonist in the treatment of sepsis syndrome: a randomized, open-label, placebo-controlled multicenter trial.

Authors:  C J Fisher; G J Slotman; S M Opal; J P Pribble; R C Bone; G Emmanuel; D Ng; D C Bloedow; M A Catalano
Journal:  Crit Care Med       Date:  1994-01       Impact factor: 7.598

9.  Targeting Rac1 by the Yersinia effector protein YopE inhibits caspase-1-mediated maturation and release of interleukin-1beta.

Authors:  Peter Schotte; Geertrui Denecker; Aeke Van Den Broeke; Peter Vandenabeele; Guy R Cornelis; Rudi Beyaert
Journal:  J Biol Chem       Date:  2004-04-01       Impact factor: 5.157

10.  Contribution of the major secreted yops of Yersinia enterocolitica O:8 to pathogenicity in the mouse infection model.

Authors:  Konrad Trülzsch; Thorsten Sporleder; Emeka I Igwe; Holger Rüssmann; Jürgen Heesemann
Journal:  Infect Immun       Date:  2004-09       Impact factor: 3.441

View more
  28 in total

Review 1.  Innate Immune Signaling Activated by MDR Bacteria in the Airway.

Authors:  Dane Parker; Danielle Ahn; Taylor Cohen; Alice Prince
Journal:  Physiol Rev       Date:  2016-01       Impact factor: 37.312

Review 2.  AIM2 in health and disease: Inflammasome and beyond.

Authors:  Puja Kumari; Ashley J Russo; Sonia Shivcharan; Vijay A Rathinam
Journal:  Immunol Rev       Date:  2020-07-26       Impact factor: 12.988

3.  The NLRP3 inflammasome contributes to host protection during Sporothrix schenckii infection.

Authors:  Amanda Costa Gonçalves; Lucas Souza Ferreira; Francine Alessandra Manente; Carolina Maria Quinello Gomes de Faria; Marisa Campos Polesi; Cleverton Roberto de Andrade; Dario Simões Zamboni; Iracilda Zeppone Carlos
Journal:  Immunology       Date:  2017-03-03       Impact factor: 7.397

4.  Chlamydia Lipooligosaccharide Has Varied Direct and Indirect Roles in Evading both Innate and Adaptive Host Immune Responses.

Authors:  Xisheng Wang; Daniel D Rockey; Brian P Dolan
Journal:  Infect Immun       Date:  2020-07-21       Impact factor: 3.441

5.  Macrophages mediate flagellin induced inflammasome activation and host defense in zebrafish.

Authors:  William J B Vincent; Christina M Freisinger; Pui-Ying Lam; Anna Huttenlocher; John-Demian Sauer
Journal:  Cell Microbiol       Date:  2015-11-04       Impact factor: 3.715

6.  In vivo evidence of inflammasome activation during spontaneous labor at term.

Authors:  Bogdan Panaitescu; Roberto Romero; Nardhy Gomez-Lopez; Yi Xu; Yaozhu Leng; Eli Maymon; Percy Pacora; Offer Erez; Lami Yeo; Sonia S Hassan; Chaur-Dong Hsu
Journal:  J Matern Fetal Neonatal Med       Date:  2018-01-17

7.  Interleukin-18 Is Critical for Mucosa-Associated Invariant T Cell Gamma Interferon Responses to Francisella Species In Vitro but Not In Vivo.

Authors:  Eric Jesteadt; Irma Zhang; Huifeng Yu; Anda Meierovics; Wei-Jen Chua Yankelevich; Siobhan Cowley
Journal:  Infect Immun       Date:  2018-04-23       Impact factor: 3.441

8.  A Role for the Inflammasome in Spontaneous Preterm Labor With Acute Histologic Chorioamnionitis.

Authors:  Nardhy Gomez-Lopez; Roberto Romero; Yi Xu; Olesya Plazyo; Ronald Unkel; Yaozhu Leng; Nandor Gabor Than; Tinnakorn Chaiworapongsa; Bogdan Panaitescu; Zhong Dong; Adi L Tarca; Vikki M Abrahams; Lami Yeo; Sonia S Hassan
Journal:  Reprod Sci       Date:  2017-01-26       Impact factor: 3.060

9.  A Role for the Inflammasome in Spontaneous Labor at Term.

Authors:  Roberto Romero; Yi Xu; Olesya Plazyo; Piya Chaemsaithong; Tinnakorn Chaiworapongsa; Ronald Unkel; Nandor Gabor Than; Po Jen Chiang; Zhong Dong; Zhonghui Xu; Adi L Tarca; Vikki M Abrahams; Sonia S Hassan; Lami Yeo; Nardhy Gomez-Lopez
Journal:  Am J Reprod Immunol       Date:  2016-03-08       Impact factor: 3.886

10.  Caspase-1 Activation Protects Lung Endothelial Barrier Function during Infection-Induced Stress.

Authors:  Diego F Alvarez; Nicole Housley; Anna Koloteva; Chun Zhou; Kristen O'Donnell; Jonathon P Audia
Journal:  Am J Respir Cell Mol Biol       Date:  2016-10       Impact factor: 6.914

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.